Additionally, we also examined if sensitization exists between pCas9‐survivin and sorafenib (SF, a widely clinically used multi‐kinases target therapy drug for HCC[36]) to treat orthotopic HCC in mice. This evidence concerns the gene BIRC5 and hepatocellular carcinoma.